Martin Pule

University College London

United Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (8)

Pedro Horna

Associate Professor

Mayo Clinic Rochester

UNITED STATES

Janosch Ortmann

University of Quebec

Claire Roddie

University Hospital

UNITED KINGDOM

Jahangir Sufi

University College London

UNITED KINGDOM

Juliana Dias Alves Pinto

Head of CAR T Cell production

University College London Hospitals NHS Foundation Trust

UNITED KINGDOM

Marc Mansour

University College London

UNITED KINGDOM

Matthew Young

Wellcome Sanger Institute

UNITED KINGDOM

Sergio Quezada

University College London

UNITED KINGDOM

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Martin Pule

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (8)

Pedro Horna

Janosch Ortmann

Claire Roddie

Jahangir Sufi

Juliana Dias Alves Pinto

Marc Mansour

Matthew Young

Sergio Quezada

Make your next move.

Martin Pule

Research Interests

Explore related searches

Contact this professor

Articles (20)

Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.

Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein-Protein Interaction.

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia.

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.

Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies

Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma

AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

Large-scale manufacturing of base-edited chimeric antigen receptor T cells.

Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors.

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Efficient clinical-grade γ-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing.

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells.

A compact and simple method of achieving differential transgene expression by exploiting translational readthrough.

Collaborators (8)

Pedro Horna

Janosch Ortmann

Claire Roddie

Jahangir Sufi

Juliana Dias Alves Pinto

Marc Mansour

Matthew Young

Sergio Quezada

Make your next move.